NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. is a Dutch public limited liability company (naamloze vennootschap) registered with the Netherlands Chamber of Commerce (KvK) under number 86649051, with its registered address at Gooimeer 2-35, 1411 DC Naarden, Netherlands. Its KvK registration status is Active. NewAmsterdam Pharma Company N.V. was incorporated in January 2022 as a Dutch private limited liability company (besloten vennootschap) and converted to a naamloze vennootschap on 21 November 2022, immediately before the closing of a business combination with Frazier Lifesciences Acquisition Corporation, a Nasdaq-listed special purpose acquisition company, through which the group’s ordinary shares began trading publicly.
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company developing oral therapies for cardiometabolic disease. Its lead product candidate, obicetrapib, is a low-dose, once-daily oral CETP inhibitor intended to lower LDL cholesterol, evaluated both as monotherapy and as a fixed-dose combination with ezetimibe. Obicetrapib has been studied in the Phase 3 BROADWAY and BROOKLYN trials in patients with established atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia, and in the ongoing PREVAIL cardiovascular outcomes trial, which completed enrollment of more than 9,500 patients in April 2024.
Ordinary shares of NewAmsterdam Pharma Company N.V. trade on the Nasdaq Global Market under the ticker symbol NAMS. For the quarter ended 31 March 2025, the company reported revenue of $3.0 million, generated under its European commercialization agreement with Menarini, together with research and development expenses of $44.8 million and a net loss of $39.5 million; it held $808.5 million in cash, cash equivalents and marketable securities as of that date. An EMA regulatory submission for obicetrapib in Europe was anticipated in the second half of 2025 through Menarini.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
2
Shareholders of NewAmsterdam Pharma Company N.V.
Two shareholders are currently disclosed for NewAmsterdam Pharma Company N.V., reflecting reportable institutional holdings rather than a complete share register. The largest disclosed holding belongs to FCPM III Services B.V., an entity affiliated with Frazier Life Sciences / Frazier Healthcare Partners, recorded at approximately 9.34% of ordinary shares (9,212,384 shares) as of 4 September 2026. Frazier-affiliated entities became shareholders through the 21 November 2022 business combination between NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation, and have since amended their position through Schedule 13D/A filings with the SEC, including a reported reduction in FCPM III Services B.V.’s stake in 2026. The second disclosed holder is Jennison Associates LLC, an institutional asset manager, recorded at approximately 3.56% of ordinary shares (3,489,221 shares) as of the same date, reported through Schedule 13G and periodic Form 13F institutional holdings filings. As a Nasdaq-listed company, public disclosure for NewAmsterdam Pharma Company N.V. captures only shareholders whose positions cross SEC reporting thresholds; smaller and non-institutional shareholders are not individually disclosed.
Data availability
Shareholder information for NewAmsterdam Pharma Company N.V. is Major shareholders only: holdings disclosed through SEC Schedule 13D, Schedule 13G and Form 13F filings are captured, while non-reportable and smaller shareholdings are not published.
Sources
- U.S. Securities and Exchange Commission, EDGAR, Schedule 13D/A filings for NewAmsterdam Pharma Co N.V. (CIK 1936258), sec.gov, retrieved 2026-09-18
- MarketBeat, institutional filing alerts referencing SEC Form 13F/13G positions for NAMS, retrieved 2026-09-18
| Shareholder | Type | Holding | Source Document |
|---|---|---|---|
| FCPM III Services B.V. | 9.3% | Netherlands Chamber of Commerce (KvK) | |
| Jennison Associates LLC | 3.6% | Netherlands Chamber of Commerce (KvK) |
Officers
14
Directors and officers of NewAmsterdam Pharma Company N.V.
Registry data for NewAmsterdam Pharma Company N.V. lists 14 active officers, drawn from the Netherlands Chamber of Commerce (KvK) source used for this profile, dated 2026-09-18. No former or resigned officers are recorded in the available data. The officer roles cover the company’s executive leadership team, including its Chief Financial Officer, Chief Business Officer, Chief Development Officer, Chief Manufacturing Officer, and Chief Legal Officer & Secretary. Two of these appointments were independently confirmed through official company announcements: Mayur Ian Somaiya was appointed Chief Financial Officer effective October 2023, and Juliette Audet was appointed Chief Business Officer effective 1 April 2024. Appointment and resignation dates for individual officers are not disclosed in the registry data reviewed. Nationality is not disclosed for any officer in the available source; the registry records a Netherlands correspondence country for each listed officer, which is not evidence of nationality or residence.
Recent officer changes
- 1 April 2024: Juliette Audet appointed Chief Business Officer (source: official company announcement).
- October 2023: Mayur Ian Somaiya (known publicly as Ian Somaiya) appointed Chief Financial Officer (source: official company announcement and SEC Form 4 filing).
Data availability
Officer information for NewAmsterdam Pharma Company N.V. is Current only: the KvK-derived registry provides active officers and job titles but does not disclose appointment dates, resignation history, nationality or occupation separately from role.
Sources
- Netherlands Chamber of Commerce (KvK), company register extract for registration 86649051, kvk.nl
- NewAmsterdam Pharma, official press release, "NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer", globenewswire.com, 23 October 2023, retrieved 2026-09-18
- SEC EDGAR, Form 4 filing for Somaiya Mayur IAN, filed 3 January 2024, retrieved 2026-09-18
Registry feed — rows exactly as filed with Netherlands Chamber of Commerce (KvK), including entries the profile above does not cover.
Group Structure
Group structure of NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. is a Nasdaq-listed public holding company. It was formed through a business combination between NewAmsterdam Pharma Holding B.V., the Dutch operating company, and Frazier Lifesciences Acquisition Corporation, a Nasdaq-listed special purpose acquisition company, completed on 21 November 2022. KvK registry linkage data associates two entities with NewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma B.V. (KvK 55971946), registered at the same address as NewAmsterdam Pharma Company N.V. (Gooimeer 2-35, 1411 DC Naarden), consistent with it being the group’s Dutch operating subsidiary; and Frazier Lifesciences Acquisition Corporation (Washington, US, registration WA 7154000), the SPAC vehicle used to complete the business combination. Ownership and voting percentages for these relationships are not disclosed in the available data. No ultimate parent company above NewAmsterdam Pharma Company N.V. is identified; its ordinary shares are publicly traded on Nasdaq and held by institutional and public investors.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| NewAmsterdam Pharma B.V. | NL | 55971946 | Direct subsidiary (per KvK registry linkage) | Ownership percentage not disclosed | Active | 2026-09-18 |
| Frazier Lifesciences Acquisition Corporation | US | WA 7154000 | Historical relationship (SPAC merger vehicle, business combination completed November 2022) | Ownership percentage not disclosed | Historical | 2026-09-18 |
Recent structural changes
- 21 November 2022: Business combination between NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation completed, creating the Nasdaq-listed NewAmsterdam Pharma Company N.V.
Data availability
Corporate-linkage information for NewAmsterdam Pharma Company N.V. is Partial: the KvK-derived registry identifies two related entities, but ownership or voting percentages are not disclosed, and no independent filing confirming NewAmsterdam Pharma B.V.’s current ownership share was located.
Sources
- Netherlands Chamber of Commerce (KvK), company register extract for registration 86649051, kvk.nl
- NewAmsterdam Pharma, official press release, "NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement", ir.newamsterdampharma.com, retrieved 2026-09-18
NewAmsterdam Pharma Company N.V.
Netherlands
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does NewAmsterdam Pharma Company N.V. do?
Clinical-stage Dutch biopharmaceutical company developing obicetrapib, an oral CETP inhibitor for LDL-C lowering in cardiometabolic disease.
Who owns NewAmsterdam Pharma Company N.V.?
Major disclosed shareholders: FCPM III Services B.V. (~9.34%) and Jennison Associates LLC (~3.56%); major-shareholders-only disclosure via SEC 13D/13G/13F filings.
Who is NewAmsterdam Pharma Company N.V.'s UBO (Ultimate Beneficial Owner)?
No verified ultimate beneficial owner identified; disclosed holders are institutional or corporate entities, not natural persons.
What is NewAmsterdam Pharma Company N.V.'s company registration number?
NewAmsterdam Pharma Company N.V.'s registration number is 86649051, filed with Netherlands Chamber of Commerce (KvK) in Netherlands. Its current status on the register is active.
Is NewAmsterdam Pharma Company N.V. still an active company?
NewAmsterdam Pharma Company N.V.'s status on Netherlands Chamber of Commerce (KvK) is listed as active.
What is NewAmsterdam Pharma Company N.V.'s registered address?
The registered address on file for NewAmsterdam Pharma Company N.V. is Naarden, Netherlands.
What is NewAmsterdam Pharma Company N.V.'s revenue?
$3.0 million reported revenue for the quarter ended 31 March 2025, from the Menarini European commercialization agreement.
Is NewAmsterdam Pharma Company N.V. listed on a stock exchange?
Nasdaq Global Market, ticker NAMS.
Who are the officers/directors of NewAmsterdam Pharma Company N.V.?
Active officers include CFO Mayur Ian Somaiya (appointed October 2023) and CBO Juliette Audet (appointed April 2024), among 14 listed officers per KvK registry data.
Does NewAmsterdam Pharma Company N.V. have a parent company or subsidiaries?
Linked to NewAmsterdam Pharma B.V. (NL, KvK 55971946), the Dutch operating subsidiary, and formed via a November 2022 business combination with Frazier Lifesciences Acquisition Corporation (US).
Can Zavia monitor changes to NewAmsterdam Pharma Company N.V.'s ownership over time?
This profile reflects a point-in-time snapshot from Netherlands Chamber of Commerce (KvK). Zavia's monitoring API can track changes to NewAmsterdam Pharma Company N.V.'s registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access NewAmsterdam Pharma Company N.V.'s data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including Netherlands, so records like NewAmsterdam Pharma Company N.V.'s registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Netherlands Chamber of Commerce (KvK) and was last synced on 18 September 2026.